Outlook Therapeutics, Inc. - Se (OTLKW)

* Successfully completed NORSE 2 enrollment in July 2020 * NORSE 1 topline results to be reported in August 2020MONMOUTH JUNCTION, N.J., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, In...

MONMOUTH JUNCTION, N.J., July 17, 2020 -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved.

Outlook Therapeutics, Inc. (OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today...

Outlook Therapeutics (OTLK) saw a big move last session, as its shares jumped 7% on the day, amid huge volumes.

Outlook Therapeutics intends to use the net proceeds from the offering for working capital and general corporate purposes, including in support of its ONS-5010 development program. The shares of comm...

In addition, the Company has entered into a definitive agreement with Syntone Ventures, LLC (“Syntone”) for the purchase and sale, in a private placement priced at-the-market under Nasdaq rules, of 82...

Outlook Therapeutics, Inc. (OTLK) (the Company), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indi...

MONMOUTH JUNCTION, N.J., June 11, 2020 -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the Company), a late clinical-stage biopharmaceutical company working to develop the first.

MONMOUTH JUNCTION, N.J., June 09, 2020 -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the Company), a late clinical-stage biopharmaceutical company working to develop the first.

Outlook Therapeutics, Inc. (OTLK) (the Company), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indi...